Analysts Set LivaNova PLC (NASDAQ:LIVN) Target Price at $59.29

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) have received an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $59.29.

LIVN has been the subject of several recent analyst reports. Wall Street Zen lowered LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Barclays reduced their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Finally, Robert W. Baird increased their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th.

LivaNova Trading Down 1.3%

Shares of NASDAQ:LIVN traded down $0.56 during midday trading on Wednesday, reaching $41.98. The company's stock had a trading volume of 514,249 shares, compared to its average volume of 628,370. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -10.26 and a beta of 0.90. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.37 and a current ratio of 1.58. The firm has a 50 day moving average price of $44.77 and a two-hundred day moving average price of $43.18. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $57.35.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently added to or reduced their stakes in LIVN. Raymond James Financial Inc. purchased a new stake in LivaNova during the fourth quarter valued at about $9,645,000. PNC Financial Services Group Inc. boosted its position in LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after acquiring an additional 1,424 shares in the last quarter. Swiss National Bank boosted its position in shares of LivaNova by 0.7% in the 4th quarter. Swiss National Bank now owns 106,819 shares of the company's stock worth $4,947,000 after purchasing an additional 700 shares in the last quarter. Vestcor Inc bought a new stake in shares of LivaNova in the 4th quarter worth approximately $204,000. Finally, Cibc World Markets Corp bought a new stake in shares of LivaNova in the 4th quarter worth approximately $236,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.